Caladrius Biosciences (CLBS) Raised to “Buy” at Zacks Investment Research

Caladrius Biosciences (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm presently has a $4.50 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 11.11% from the stock’s previous close.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Caladrius Biosciences in a report on Friday, May 11th. ValuEngine upgraded Caladrius Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Chardan Capital raised their price objective on Caladrius Biosciences from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Friday, March 23rd.

Shares of CLBS stock traded up $0.04 during mid-day trading on Friday, hitting $4.05. 9,921 shares of the company’s stock were exchanged, compared to its average volume of 60,064. Caladrius Biosciences has a fifty-two week low of $2.63 and a fifty-two week high of $6.35. The stock has a market capitalization of $38.66 million, a price-to-earnings ratio of -2.28 and a beta of 1.25.

Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.28. sell-side analysts forecast that Caladrius Biosciences will post -2.51 EPS for the current year.

A number of institutional investors have recently modified their holdings of CLBS. Macquarie Group Ltd. boosted its holdings in Caladrius Biosciences by 321.0% in the fourth quarter. Macquarie Group Ltd. now owns 29,890 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 22,790 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Caladrius Biosciences in the first quarter valued at $110,000. Finally, Dimensional Fund Advisors LP acquired a new position in Caladrius Biosciences in the first quarter valued at $197,000. Hedge funds and other institutional investors own 7.80% of the company’s stock.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply